CN109563092B - 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 - Google Patents

可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 Download PDF

Info

Publication number
CN109563092B
CN109563092B CN201780043024.7A CN201780043024A CN109563092B CN 109563092 B CN109563092 B CN 109563092B CN 201780043024 A CN201780043024 A CN 201780043024A CN 109563092 B CN109563092 B CN 109563092B
Authority
CN
China
Prior art keywords
pyridin
phenyl
imidazo
amine
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780043024.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563092A (zh
Inventor
H.梅尔斯德特
S.比斯特朗姆
J.瓦格伯格
E.奥森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kancera AB
Original Assignee
Kancera AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kancera AB filed Critical Kancera AB
Publication of CN109563092A publication Critical patent/CN109563092A/zh
Application granted granted Critical
Publication of CN109563092B publication Critical patent/CN109563092B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780043024.7A 2016-07-11 2017-07-10 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 Expired - Fee Related CN109563092B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16178928.4 2016-07-11
EP16178928 2016-07-11
PCT/EP2017/067262 WO2018011138A1 (en) 2016-07-11 2017-07-10 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity

Publications (2)

Publication Number Publication Date
CN109563092A CN109563092A (zh) 2019-04-02
CN109563092B true CN109563092B (zh) 2021-09-14

Family

ID=56409027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043024.7A Expired - Fee Related CN109563092B (zh) 2016-07-11 2017-07-10 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物

Country Status (7)

Country Link
US (1) US11008318B2 (https=)
EP (1) EP3481824B1 (https=)
JP (1) JP6891262B2 (https=)
KR (1) KR102466810B1 (https=)
CN (1) CN109563092B (https=)
ES (1) ES2899113T3 (https=)
WO (1) WO2018011138A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019162458A1 (en) * 2018-02-23 2019-08-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases
CN112574176B (zh) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
EP4215525A4 (en) * 2020-09-17 2024-08-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Piperazine derivative, preparation method therefor and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684964A (zh) * 2002-08-14 2005-10-19 阿斯利康(瑞典)有限公司 一些新的咪唑并吡啶及其用途
WO2013100631A1 (en) * 2011-12-28 2013-07-04 Hanmi Pharm. Co., Ltd. Novel imidazopyridine derivatives as a tyrosine kinase inhibitor
CN104936963A (zh) * 2012-11-20 2015-09-23 Ktb肿瘤研究有限责任公司 作为蛋白激酶抑制剂的硫醚衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002349477A1 (en) 2001-11-26 2003-06-10 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
SE0202464D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
US7786113B2 (en) 2004-12-23 2010-08-31 Hoffman-La Roche Inc. Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
US7618964B2 (en) 2004-12-23 2009-11-17 Hoffmann-La Roche Inc. Benzamide derivatives, their manufacture and use as pharmaceutical agents
PL1861387T3 (pl) 2005-01-28 2014-08-29 Dae Woong Pharma Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
EP1891069A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1963315B1 (en) 2005-12-22 2014-10-08 Cancer Research Technology Limited Enzyme inhibitors
US20090170847A1 (en) 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
RU2009135616A (ru) 2007-03-30 2011-05-10 Астразенека Аб (Se) НОВЫЕ АМИДАЗО[4,5-b]ПИРИДИН-7-КАРБОКСАМИДЫ 704
WO2008121064A1 (en) 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
ES2392482T3 (es) 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
WO2011066211A1 (en) 2009-11-24 2011-06-03 Glaxosmithkline Llc Azabenzimidazoles as fatty acid synthase inhibitors
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
EP3253754B1 (en) * 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684964A (zh) * 2002-08-14 2005-10-19 阿斯利康(瑞典)有限公司 一些新的咪唑并吡啶及其用途
WO2013100631A1 (en) * 2011-12-28 2013-07-04 Hanmi Pharm. Co., Ltd. Novel imidazopyridine derivatives as a tyrosine kinase inhibitor
CN104936963A (zh) * 2012-11-20 2015-09-23 Ktb肿瘤研究有限责任公司 作为蛋白激酶抑制剂的硫醚衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKe kinases》;Wang T;《Bioorganic & Medicinal Chemistry Letters》;20120114;第22卷;参见第2064页表1 *

Also Published As

Publication number Publication date
JP6891262B2 (ja) 2021-06-18
US20200024272A1 (en) 2020-01-23
US11008318B2 (en) 2021-05-18
EP3481824A1 (en) 2019-05-15
CN109563092A (zh) 2019-04-02
KR102466810B1 (ko) 2022-11-11
EP3481824B1 (en) 2021-10-20
KR20190026006A (ko) 2019-03-12
ES2899113T3 (es) 2022-03-10
WO2018011138A1 (en) 2018-01-18
JP2019520412A (ja) 2019-07-18

Similar Documents

Publication Publication Date Title
CN109563092B (zh) 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
JP6253631B2 (ja) Ａｘｌインヒビターとして有用な置換トリアゾール
CN119923401A (zh) 新型四杂环化合物
CN107567445B (zh) 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2-苯基-3h-咪唑并[4,5-b]吡啶衍生物
EA020807B1 (ru) Соединения пиридина
CN107074812B (zh) 取代的嘧啶化合物
CN103124730A (zh) 杂环炔苯类化合物及其药用组合物和应用
KR20220028072A (ko) Bet 억제제로서의 헤테로시클릭 화합물
JP7625141B2 (ja) Ｅｒｂｂ２の阻害剤としての縮合四環キナゾリン誘導体
CN110294761B (zh) 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
WO2016208592A1 (ja) 二環性複素環アミド誘導体
TW202446368A (zh) 經取代之吡咯啶及吡咯啶酮化合物
KR20100097077A (ko) Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체
CN112939948B (zh) 新型含喹唑啉类化合物及其中间体与应用
US11660303B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
JP2025539873A (ja) Ｈｕｒ（ｅｌａｖｌ１）を調節するための化合物
CN113563341A (zh) 作为Trk抑制剂的取代的吡唑并[1,5-a]嘧啶化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210914